On July 18, 2022, the selection results of the seventh batch of national centralized drug procurement were officially announced, and Ondansetron hydrochloride injection of our company was selected
    Our ondansetron hydrochloride injection (2ml: 4mg; 4ml: 8mg) is prepared with the original product Zofran® as the reference preparation according to the technical requirements of quality and efficacy consistency evaluation.
    Ondansetron is a selective 5-HT3 receptor antagonist, which can effectively suppress or relieve nausea and vomiting caused by cytotoxic chemotherapy drugs and radiotherapy. Ondansetron has a rapid and powerful inhibitory effect on vomiting caused by some strong emetic chemotherapy drugs (such as cisplatin, cyclophosphamide, etc.). This product is suitable for controlling nausea and vomiting caused by cancer chemotherapy and radiation therapy; It is also suitable for the prevention and treatment of postoperative nausea and vomiting.